Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarc ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

作者：行情君 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 本文源自：金融界 8月25日，天境生物(IMAB)开盘上涨4.13%，截至21:30，报5.3美元/股，成交23.77万美元，总市值6.09 亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 大事提醒： ...

Core Insights - I-Mab has appointed independent directors Dr. Robert Lenz and Ms. Xin Liu to its Board of Directors, effective August 22, 2025, and reiterated the appointment of Dr. Sean Cao as of May 28, 2025 [1][2][6] - The company has established a Research and Development Committee, chaired by Dr. Robert Lenz, to enhance its focus on R&D excellence and innovation [2][6] - Dr. Ken Takeshita has been appointed to the Scientific Advisory Board to strengthen I-Mab's capabilities in immuno-oncology [2][6] Company Developments - The new appointments are aimed at supporting I-Mab's strategic agenda and enhancing the Board's expertise as the company progresses with its lead product, givastomig [2][6] - Givastomig is a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers, currently in Phase 1 trials, showing strong tumor-binding and anti-tumor activity [8] Board Member Profiles - Dr. Robert Lenz has extensive experience in R&D, previously serving as Executive Vice President at Neumora Therapeutics and holding key roles at Amgen and Abbott Laboratories [2][3] - Ms. Xin Liu is a finance executive with a background in healthcare investments, currently serving as Investment Director at Hony Capital [3][4] - Dr. Sean Cao is a biotech entrepreneur with a strong background in founding and leading biotech companies, currently an Operating Partner at CBC Group [4][5] - Dr. Ken Takeshita is a recognized biopharmaceutical executive with experience in clinical development and research, currently the Global Head of R&D for Daiichi Sankyo [5][6]

8月22日，天境生物(IMAB)开盘上涨5.94%，截至21:30，报4.99美元/股，成交21.41万美元，总市值5.74 亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 大事提醒： 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 本文源自：金融界 作者：行情君 ...

Core Viewpoint - Tianjing Bio (IMAB) has shown significant growth in revenue and is preparing to release its fiscal year 2024 mid-term report, indicating a focus on innovative biopharmaceuticals in oncology and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1]. - The company's mission is to create groundbreaking innovative biopharmaceuticals to address unmet clinical needs and improve the quality of life for patients globally [1].

Cantor Global Healthcare Conference Format: One-on-one meetings Date: September 3-5, 2025 ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the following upcoming investor conferences in September, 2025: H.C. Wainwright 27 Annual Global Investment Conference Conference details a ...

本文源自：金融界 作者：行情君 大事提醒： 8月28日，天境生物(美东)盘前披露2024财年中报（数据来源于纳斯达克官网，预计披露日期为美国当 地时间，实际披露日期以公司公告为准）。 资料显示，天境公司是一家境外注册成立的离岸控股母公司,通过境内子公司天境生物开展业务。天境 生物是一家聚焦于肿瘤免疫和自身免疫领域的创新生物药企业,公司高度专注于在全球范围内开发具 有"全球首创"和"同类最优"潜力的创新生物药。公司的使命是研制具有突破性的创新生物药,填补临床 治疗需求的空白,并且切实提高全球患者的生存质量。为了实现这个目标,公司正在努力成为一家扎根中 国、面向全球的领先生物医药公司。 8月20日，天境生物(IMAB)开盘上涨10.2%，截至21:32，报4.64美元/股，成交56.44万美元，总市值5.34 亿美元。 财务数据显示，截至2023年12月31日，天境生物收入总额2764.4万人民币，同比增长112.48%；归母净 利润-14.66亿人民币，同比增长41.54%。 ...

Exhibit 99.1 I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update ROCKVILLE, MD, August 20, 2025 – I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progress and business updates. "The first half of 2025 has been transformative for I-Mab," sai ...

ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progress and business updates. "The first half of 2025 has been transformative for I-Mab," said Sean Fu, PhD, Chief Executive Officer of I- Mab. "Our presentation at ESMO ...